SII – Bibliografia Print E-mail


  1. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92:1885-1893.
  2. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl 2): 43-47.
  3. Manning AP, Thompson WG, Heaton KW, et al. Towards a positive diagnosis of the irritable bowel. B Med J 1978; 2:653-654
  4. Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1-7
  5. Thompson WG, Dotevall G, Drossman DA, et al. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterology International. 1989;2:92-95
  6. Agréus L, Svärdsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995;109:671-680
  7. Triadafilopoulos G, Simms RW, Goldenberg L. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci 1991; 36:59-64
  8. Sivri A, Cindas A, Dincer B, Sivri B. Bowel dysfunction in irritable bowel syndrome in fibromyalgia patients. Clin Rheum 1996; 15:283-286
  9. Prior A, Wilson K, Whorwell PJ, Faragher EB. Irritable bowel syndrome in the gynecological clinic. Survey of 798 new referrals. Dig Dis Sci 1989;34:1820-1824
  10. Francis CY, Duffy JN, Whorwell PJ, Morris J. High prevalence of irritable bowel syndrome in patients attending urological outpatient departments. Dig Dis Sci 1997;42:404-407
  11. Longstreth GF, Preskill DB, Youkeles Y. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome. Dig Dis Sci 1990; 1285-1290
  12. Hahn BA, Kirchdoerfer LJ, Fullertons S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11:553-559
  13. Talley NJ, O’Keefe EA, Zinsmeister AR, Melton LJ. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology 1992;102:895-901
  14. Drossman DA, Li Z, Andruzzi E, Temple RD, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569-1580
  15. Heaton KW, O’Donnell LD, Braddon FM, et al. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992, 102:1962-7
  16. Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors and health care utilization. Am J Epidemiol 1995;142:76-83
  17. Bazzocchi G, Ellis J, Meyer J, et al. Colonic scintigraphy and manometry in constipation, diarrhea and inflammatory bowel disease. Gastroenterology 1988;94:A29
  18. Bazzocchi G, Ellis J, Villaneuva-Meyer J, et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology 1990;98:686-693
  19. Aggarwal A, Cutts TF, Abell TL, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology 1994; 106:45-50
  20. Taylor I, Basu P, Hammond P, Darby C, Flynn M. Effect of bile acid perfusion on colonic motor function in patients with the irritable colon syndrome. Gut 1980; 21:843-847
  21. Narducci F, Snape WJJ, Battle WM et al. Increased colonic motility during exposure to a stressful situation. Dig Dis Sci 1985; 30:40-44
  22. Whitehead WE Holtkotter B, Enck P et al. Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-1192
  23. Mertz H, Naloboff, Munakata J et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52
  24. Trimble KC, Farouk R, Pryde A et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific evidence for a generalized disorder of gut sensitivity. Dig dis Sci 1995; 40:1607-1613
  25. Cook IJ, Van Eden A, Collins SM. Patients with irritable bowel syndrome have a greater pain tolerance than normal subjects. Gastroenterology 1987; 93:727-733
  26. Silvermann DHS Munakata JA, Ennes H, et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112: 64-72
  27. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318:565-567
  28. McKendrick MW, Read NW. Irritable bowel syndrome – post salmonella infection. J Infect 1994; 29:1-3
  29. Weston AP, Biddle WL, Bhatia PS, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38: 1590-1595
  30. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779-82
  31. Gwee KA, Graham JC, McKendrick MW, et al. Psychological scores and persistence of irritable bowel after infectious diarrhea. Lancet 1996; 347:150-153
  32. Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome: a multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988; 95:701-708
  33. Delvaux M, Denis P, Allemans H. Sexual and physical abuse are more frequently reported by IBS patients than by patients with organic digestive diseases or controls: results of a multicentre inquiry. Eur J Gastroenterol Hepatol 1997; 9: 345-352
  34. Jones VA, McLaughlan P, Shorthouse M, et al. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982; 2:1115-1117
  35. Nanda R, James R, Smith H, et al. Food intolerance and the irritable bowel syndrome. Gut 1989; 30:1098-1104
  36. Benghtsson U, Nilsson-Balknas U, Hanson LA, et al. Double blind, placebo controlled food reactions do not correlate to IgE allergy in the diagnosis of staple food related gastrointestinal symptoms. Gut 1996; 39:130-135
  37. Hamm LR, Sorrells SC, Harding JP, et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling Rome criteria. Am J Gastroenterol 1999; 94:1279-1282
  38. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94:2912-2917
  39. Thompson WG, Heaton KW, Smythe GT, et al. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol 1997; 9:689-692
  40. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333:1-4
  41. Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984; 25:168-173
  42. Whorwell PJ, Prior A, Faragher EB. Hypnotherapy in irritable bowel syndrome. Lancet 1984; ii:1232-4
  43. Svedlund J. Psychotherapy in irritable bowel syndrome: a controlled outcome study. Acta Psychiatr Scand 1983;67:1-86
  44. Guthrie E, Creed F, Dawson D, Tomerson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991;100:450-457
  45. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-283
  46. Chiotakakou-Faliakou E, Kamm MA, Roy AJ, et al. Biofeedback provides long-term benefit for patients with intractable, slow and normal transit constipation. Gut 1998; 42:517-521
  47. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systemic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-147
  48. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8:499-510
  49. Evans PR, Bak Y-T, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther 1996; 10:787-793
  50. Washington N, Ridley P, Thomas E, et al. Mebeverine decreases mass movements and stool frequency in lactulose –induced diarrhoea. Alimeth Pharmacol Ther 1998; 12:583-588
  51. Daly J, Bergin A, Sun WM, Read NW. Effect of food and anti-colinergic drugs on the pattern of rectosigmoid contractions 1993
  52. Van Outryve M, Mayer S, Meeus MA, et al. A double blind cross-over comparison study of safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Phaem Ther 1995; 20:277-282
  53. Clouse RE, Lustman PJ. Antidepressant therapy in 138 patients with irritable bowel syndrome; a five year clinical experience. Aliment Pharmacol Ther 1994; 8: 409-416
  54. Cadau G, Pallotta N, Badiali D, Corazziari E. L’impiego degli antidepressivi triciclici a basso dosaggio nel trattamento dei disturbi funzionali del tratto gastrointestinale superiore ed inferiore. Neurogastroenterologia 1998; 4:16-20
  55. Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000; 46:522-526
  56. Read M, Read NW, Barber DC, Duthie HL. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 1982;27:807-814.
  57. Cann PA, Read NW, Holdsworth CD, et al . Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984; 29:239-247
  58. Luman W, Williams AJ, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption: long-term outcome. Eur J Gastroenterol Hepatol 1995;7:641-645
  59. Scarpignato C, Pelosini I. Novel drugs for treatment of functional gastrointestinal disorders. In: Approach to the patient with chronic gastrointestinal disorders. Corazziari E, Ed; Messaggi srl, Milano, Italy 1999: pp429-474
  60. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome. Gastroenterology 2000;118:463-468
  61. Emmanuel AV, Nicholls T, Roy AJ, et al. Prucalopride improves colonic transit and stool frequency in patients with slow and normal transit constipation. Gastroenterology 2000; 118: (Suppl. 2 pt 1):A846:4438
  62. Schikowski A, Mathis C, Thewissen M, et al. Dose-dependent modulation of rectal afferent sensitivity with 5-HT4 receptor partial agonist. Gastroenterology 1999;116:A643
  63. Müller-Lissner S, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relievs key symptoms of irritable bowel syndrome. Gastroenterology 2000; 118: (Suppl. 2 pt 1):A175:1000
  64. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355:1035-10.40
  65. Stacher G, Weber U, Stacher-Jannotta G, et al. Effects of 5.HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial. Br J Clin Pharmacol 2000; 49:429-436
  66. Corazziari E. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 1999; 13 Suppl A:71A-75A1642
  67. Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. Dig Dis Sci 1995; 40:2244-2248